Immunotherapy-Chemo combo aims to make inoperable esophageal cancer removable
Disease control
Ongoing
This phase 2 trial tests whether combining the immunotherapy drug cardenilimab with standard chemotherapy can shrink locally advanced esophageal cancer that cannot be surgically removed at first. The goal is to turn these tumors into operable ones, potentially improving survival.…
Phase: PHASE2 • Sponsor: Li Zhang • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC